Medical Updates

Inclisiran Injection Every Six Months Substantially Reduced LDL-C in Patients with Elevated LDL-C

Subcutaneous inclisiran injections at day 1, 90 and then every six months can bring about substantial reductions in low-density lipoprotein...

31 Mar, 2020

Email this page
Insights from EPICORE Asia: Antithrombotic Management Patterns and Long-term Outcomes in Asian ACS Patients undergoing PCI

A real-world study that analysed data from the EPICOR Asia study reaffirmed that many patients with acute coronary syndrome (ACS) underwent...

31 Mar, 2020

Email this page
Combination Antihypertensive Therapy and the Risk of developing Hypokalemia in Hypertensives

The impact of antihypertensive combination therapy on the risk of hypokalemia is unclear as of now. A recent study revealed hypokalemia to be a...

26 Mar, 2020

Email this page
Discontinuation of RAS Blockade in Individuals with Low eGFR Associated with Increased Death and MACE

It is not known whether discontinuation of renin-angiotensin system blockade when estimated glomerular filtration rate (eGFR) falls below 30 mL/min/...

20 Mar, 2020

Email this page

Key Trials

The FAST-MI Programme: A Comparison of Five-year Outcomes in STEMI Patients Treated with Early pPCI, Late pPCI or Pharmacoinvasive Strategy

A substantial proportion of STEMI patients are treated with primary PCI beyond the recommended time frame (late pPCI). Implementing a...

Prasugrel Renders Superior Efficacy vs. Ticagrelor in ACS Patients Undergoing Invasive Evaluation

According to the trial, prasugrel was associated with a greater reduction of composite of death, MI and stroke at one year without increased...

SMART-DATE Trial: Long-Term DAPT-The Standard of Care for ACS Patients Undergoing PCI with DES

The SMART-DATE trial recommends that ACS patients undergoing PCI with DES be treated with prolonged DAPT (at least 12 months) rather than short-term...

Long Term Treatment with Riociguat Sustains Clinical Benefits for upto One Year in CTPH

Long-term treatment with riociguat had a favorable benefit-risk profile in patients with inoperable chronic thromboembolic pulmonary hypertension (...

Slide Library

Medical Management Strategy of CTEPH: Role of Riociguat

Riociguat, a stimulator of soluble guanylate cyclase, has been globally approved for the treatment of PAH and inoperable CTEPH and persistent/...

Email this page
Macitentan: 1st ERA Proven to Reduce Morbidity and Mortality in PAH

Macitentan is an orally active, potent, tissue targeting ERA that is indicated for the treatment of pulmonary arterial hypertension (PAH). It is the...

Email this page
Chronic Thromboembolic Pulmonary Hypertension

Chronic thromboembolic pulmonary hypertension (CTEPH) is the presence of mean pulmonary artery pressure (mPAP) ≥ 25 mmHg following an episode of...

Email this page
Diabetic Dyslipidemia

Dyslipidemia is one of the key risk factors for cardiovascular disease (CVD) in diabetes mellitus. This slide set provides information on the...

Email this page

Our Publications

Mexohar (Mexiletine) Monograph

About 5% of patients with cardiac arrhythmias or with heart failure are diagnosed with a ventricular tachycardia. Recurrent Ventricular Tachycardia...

Gutron (Midodrine hydrochloride) Monograph

Orthostatic Hypotension is common in elderly (>70 years of age) and can also occur secondary to neuropathy like in diabetes or central lesions...

Azmarda (Sacubitril/Valsartan) FAQs

This booklet on frequently asked questions on sacubitril/valsartan, the first-in-class angiotensin receptor neprilysin inhibitor (ARNI) provides...

Retefast (Reteplase) Datasheet

This datasheet provides an overview on the pharmacology, clinical efficacy, safety, indications and dosage of reteplase.

Patient Education

Understanding Angioplasty

Angioplasty is a life-saving procedure to open up blocked or narrowed blood vessels. This document gives a brief idea about the procedure.

Understanding Obesity

This document explains what is obesity, what is the impact of obesity on overall health and what are the benefits of weight loss. 


Know more about the risk factors, associated ill-effects and tips for management of hypertension or high blood pressure. 


What percent of your patients who need oral anticoagulation, receive warfarin?
25% (5 votes)
20% (4 votes)
10% (2 votes)
15% (3 votes)
25% (5 votes)
Almost all
5% (1 vote)
Total votes: 20